Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 21/01/2025 GMT			5-day change	1st Jan Change
731.50 ^DKK	+4.95%		+4.65%	+2.24%

01-13	Zealand Pharma A/S Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 02:15 PM
01-07	Jefferies lowers target price for Zealand Pharma to DKK 1,050 (1,100), reiterates Buy	FW

Bank of America initiates coverage of Zealand Pharma with Buy and target price of DKK 1,100 - BN

October 15, 2024 at 08:22 am

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ZEALAND PHARMA A/S	731.50DKK	+4.95%	+4.65%	6.87B
	BANK OF AMERICA CORPORATION	46.70USD	+0.38%	+1.89%	354B

Latest news about Zealand Pharma A/S

Zealand Pharma A/S Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 02:15 PM	01-13
Jefferies lowers target price for Zealand Pharma to DKK 1,050 (1,100), reiterates Buy	01-07	FW
Deutsche Bank lowers target price for Zealand Pharma to 750 Danish kroner (815), reiterates hold	12-23	FW
Zealand Pharma A/S(CPSE:ZEAL) added to OMX Nordic 40 Index	12-22	CI
Zealand Pharma Shares Fall After FDA Pushes Back Bowel-Disease Drug	12-20	DJ
DNB lowers target price for Zealand Pharma to DKK 1,010 (1,050), reiterates Buy - BN	12-20	FW
Correction: Zealand Pharma Gets US FDA's Complete Response Letter for Short Bowel Syndrome Drug	12-20	MT
FDA wants an additional study from Zealand Pharma for glepaglutide	12-20	FW
BTIG lowers target price for Zealand Pharma to DKK 1,050 (1,100), reiterates Buy - BN	12-20	FW
Goldman Sachs lowers target price for Zealand Pharma to DKK 1,004 (1,095), reiterates Buy - BN	12-20	FW
Zeland Pharma Gets US FDA's Complete Response Letter for Short Bowel Syndrome Drug	12-20	MT
Zealand Pharma Fails to Get FDA Approval for Short Bowel Syndrome Drug	12-19	MT
Zealand Pharma Falls Short of FDA Approval for Glepaglutide	12-19	DJ
Zealand Pharma A/S Announces U.S. Food and Drug Administration Issues Complete Response Letter for the New Drug Application for the Treatment of Short Bowel Syndrome	12-19	CI
Kempen lowers target price for Zealand Pharma to DKK 900 (960), reiterates Buy - BN	12-18	FW
DNB Markets Kicks Off Zealand Pharma's Coverage at Buy	12-12	MT
DNB initiates coverage of Zealand Pharma with Buy and target price DKK 1,050 - BN	12-12	FW
Swedbank Robur Småbolagsfond Norden decreased 2.03 percent in November - added Netcompany to the portfolio	12-09	FW
Zealand Pharma A/S Presents at Jefferies London Healthcare Conference 2024, Nov-21-2024 09:30 AM	11-21
KBC Securities Initiates Zealand Pharma at Buy	11-20	MT
Zealand Pharma rallies after JP Morgan initiates Overweight rating	11-08	FW
Danske Bank raises Zealand Pharma to 'Keep' (Sell), target price 825 Danish kroner - BN	11-08	FW
Goldman Sachs lowers target price for Zealand Pharma to DKK 1,095 (1,106), reiterates Buy - BN	11-08	FW
JP Morgan initiates coverage of Zealand Pharma with Overweight and target price of DKK 1,100 - BN	11-08	FW
Zealand Pharma A/S, Q3 2024 Earnings Call, Nov 07, 2024	11-07

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2023, the Group had a portfolio of 7 products in clinical development (including 3 in phase III, 3 in phase II and 1 in phase I), and 3 products in preclinical development.

Employees

298

Sector

Biotechnology & Medical Research

Calendar

20/02/2025 - Q4 2024 Earnings Release

More about the company